LISTING OF THE CLAIMS READABLE ON ELECTED SPECIES

16. (new) A process for analyzing gene function comprising: a) injecting a naked oligonucleotide into a blood vessel lumen, *in vivo* ; b) increasing the propensity for macromolecules to move through vessel walls and enter the extravascular space; and, c) delivering the naked oligonucleotide to an extravascular cell outside of the blood vessel via the increased permeability.
17. (currently amended) The process of claim [[4]] 16 wherein the oligonucleotide consists of a single strand oligonucleotide.
18. (currently amended) The process of claim [[5]] 17 wherein the single strand oligonucleotide consists of anti-sense oligonucleotide.
19. (currently amended) The process of claim [[6]] 18 wherein the single strand oligonucleotide consists of an artificial oligonucleotide.
20. (currently amended) The process of claim [[4]] 16 wherein the oligonucleotide consists of double strand nucleic acid.
21. (currently amended) The process of claim [[8]] 20 wherein the double strand oligonucleotide comprises RNA.
22. (currently amended) The process of claim [[4]] 16 wherein delivery of the oligonucleotide to the cell results in decreased expression of the gene.
23. (currently amended) The process of claim [[9]] 21 wherein the double strand oligonucleotide consists of a nucleic acid sequence comprising 10 to 50 bases.
24. (currently amended) The process of claim [[11]] 23 wherein the double strand oligonucleotide consists of a nucleic acid sequence comprising 18 to 25 bases.
25. (currently amended) The process of claim [[4]] 16 wherein the oligonucleotide comprises sequence that is similar to a portion of the gene sequence.
26. (currently amended) The process of claim [[10]] 22 wherein the gene is an endogenous gene.
27. (currently amended) The process of claim [[15]] 22 wherein the gene is a viral gene.

COMPLETE LISTING OF THE CLAIMS

In the claims, please withdraw claims 13-15 and 28-29, and amend claims 14-15 and 17-29 as follows:

13. (withdrawn) A process for analyzing gene function comprising: a) injecting a naked polynucleotide encoding the gene into a blood vessel lumen, *in vivo* ; b) increasing the propensity for macromolecules to move through vessel walls and enter the extravascular space; and, c) delivering the naked polynucleotide to an extravascular cell outside of the blood vessel.
14. (withdrawn) The process of claim [[1]] 13 wherein the polynucleotide consists of a gene.
15. (withdrawn) The process of claim [[1]] 13 wherein the gene encodes a protein.
16. (original) A process for analyzing gene function comprising: a) injecting a naked oligonucleotide into a blood vessel lumen, *in vivo* ; b) increasing the propensity for macromolecules to move through vessel walls and enter the extravascular space; and, c) delivering the naked oligonucleotide to an extravascular cell outside of the blood vessel via the increased permeability.
17. (currently amended) The process of claim [[4]] 16 wherein the oligonucleotide consists of a single strand oligonucleotide.
18. (currently amended) The process of claim [[5]] 17 wherein the single strand oligonucleotide consists of anti-sense oligonucleotide.
19. (currently amended) The process of claim [[6]] 18 wherein the single strand oligonucleotide consists of an artificial oligonucleotide.
20. (currently amended) The process of claim [[4]] 16 wherein the oligonucleotide consists of double strand nucleic acid.
21. (currently amended) The process of claim [[8]] 20 wherein the double strand oligonucleotide comprises RNA.
22. (currently amended) The process of claim [[4]] 16 wherein delivery of the oligonucleotide to the cell results in decreased expression of the gene.
23. (currently amended) The process of claim [[9]] 21 wherein the double strand oligonucleotide consists of a nucleic acid sequence comprising 10 to 50 bases.

24. (currently amended) The process of claim [[11]] 23 wherein the double strand oligonucleotide consists of a nucleic acid sequence comprising 18 to 25 bases.
25. (currently amended) The process of claim [[4]] 16 wherein the oligonucleotide comprises sequence that is similar to a portion of the gene sequence.
26. (currently amended) The process of claim [[10]] 22 wherein the gene is an endogenous gene.
27. (currently amended) The process of claim [[15]] 22 wherein the gene is a viral gene.
28. (withdrawn) The process of claim [[1]] 13 wherein analyzing gene function comprises drug design.
29. (withdrawn) The process of claim [[4]] 16 wherein analyzing gene function comprises drug design.